SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03161431 |
|
Recruitment Status :
Recruiting
First Posted : May 19, 2017
Last Update Posted : May 13, 2024
|
Sponsor:
Syntrix Biosystems, Inc.
Collaborators:
Massachusetts General Hospital
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Mayo Clinic
University of Rochester
M.D. Anderson Cancer Center
University of Miami
Information provided by (Responsible Party):
Syntrix Biosystems, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2025 |
| Estimated Study Completion Date : | June 2026 |